Crouch ER, Kraker RT, Wallace DK, et al. - Using a masked, multicenter, phase 1 dose de-escalation study design, researchers conducted this prospective cohort study to assess ocular outcomes at 12 months’ corrected age for eyes receiving a dose of 0.625 mg, 0.25 mg, 0.125 mg, 0.063 mg, or 0.031 mg of bevacizumab for type 1 retinopathy of prematurity. This investigation was carried out from April 2016 to October 2017. Twelve eyes had myopia greater than −5.00 D spherical equivalent and 2 eyes had hyperopia greater than 5.00 D spherical equivalent in this cohort study of 46 infants (87 eyes). In this low-dose bevacizumab study, the secondary outcomes of high myopia, strabism, retinal detachment, nystagmus, and other 1-year ocular abnormalities are consistent with levels recorded in other higher-dose studies.